IGF2BP1 and breast neoplasm: For example, significantly augmented promoter methylation of IGF2BP1 leads to more common silencing events with respect to IGF2BP1 in metastatic breast tumor cells compared to methylation observed in non-metastatic breast tumor cells (Gu, et al., 2012).